What's breaking now, across thousands of outlets.
Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
High blood levels of xylitol associated with higher risk of major cardiovascular events, in largest study of its kind A common sweetener used in products such as chewing gum, toothpaste, jam, yoghurts…
Pharma news from the Pharmalot campus, brought to you by the Pharmalittle newsletter
Since Alzheimer’s disease researcher José Luna-Muñoz assumed leadership of the facility—Latin America’s oldest—in 2011, he has been acquiring additional tissue types and is working to expand donor…
Britain's largest cinema chain said it has seen almost 10million guests this summer, an increase of a third on last year and the best summer intake since 2019.
The confirmation of Australia's first mainland death of a mammal from bird flu last week highlights New Zealand's challenge in managing the deadly H5N1 strain of the virus.
Bixlenvo combines two existing Gilead drugs into a single tablet for adults whose virus is suppressed but who can't use current one-pill options
